Results 131 to 140 of about 94,936 (269)

Limb Compression Therapy and Chemotherapy‐Induced Peripheral Neuropathy in Women With Gynecologic Cancers: A Prospective Self‐Controlled Study(NEURO‐GLOVE Trial)

International Journal of Cancer, Volume 159, Issue 9, Page 2300-2313, 1 November 2026.
With no effective drug‐based prevention strategies available for chemotherapy‐induced peripheral neuropathy (CIPN), research in neuroprotective approaches has grown. Of particular interest is mechanical compression, which may protect nerves by temporarily reducing blood flow during treatment. The authors here conducted a prospective trial in women with
Kadriye Başkurt, Galip Can Uyar, Enes Yeşilbaş, Fatma Zehra Altunç, Damla Erimhan Çevik, İsmet Murat Melek, Yasemin Eren, Ömür Berna Çakmak Öksüzoğlu, Kadriye Bir Yücel, Antonio Di Meglio, Isabelle Ray‐Coquard, Osman Sütcüoğlu   +11 more
wiley   +1 more source

Chemotherapy‐Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline‐Free Regimen With Docetaxel, Cyclophosphamide—Results From a Randomized Clinical Trial

International Journal of Cancer, Volume 159, Issue 8, Page 1990-2003, 15 October 2026.
Chemotherapy‐induced nausea and vomiting (CINV) remains a significant clinical problem despite modern antiemetics. In particular, antiemetic strategies for emerging cancer therapies lack detailed evaluation. This randomized trial analyzed hourly CINV data for patients with early breast cancer who received either docetaxel plus cyclophosphamide (TC) or ...
Manuel Hörner, Henning Schäffler, Lothar Häberle, Chloë Goossens, Kerstin Pfister, Elena Leinert, Kristina Veselinovic, Sara Y. Brucker, Uwe Köhler, Georg Heinrich, Andreas Schneeweiss, Matthias W. Beckmann, Peter A. Fasching, Wolfgang Janni, Brigitte Rack, Sabine Heublein, Philipp Ziegler   +16 more
wiley   +1 more source

Plasma PlGF as a Potential Biomarker in Ramucirumab‐Based Second‐Line Therapy for Advanced Gastroesophageal Adenocarcinoma: Exploratory Biomarker Analysis from the Phase II Part of the RAMIRIS Trial

International Journal of Cancer, Volume 159, Issue 7, Page 1817-1828, 1 October 2026.
Antiangiogenic treatment with ramucirumab is a standard second‐line option in advanced gastric and gastroesophageal junction adenocarcinoma. However, reliable biomarkers are currently lacking. This exploratory biomarker analysis of the RAMIRIS trial suggests that elevated baseline and early on‐treatment levels of the pro‐angiogenic placental growth ...
Jurek Hille, Sylvie Lorenzen, Claudia Pauligk, Victoria Gensch, Peter Thuss‐Patience, Eray Goekkurt, Thomas Ettrich, Florian Lordick, Carsten Bokemeyer, Christian Müller, Peter Reichardt, Martin Sökler, Daniel Pink, Stefan Probst, Thorsten O. Goetze, Salah E. Al‐Batran, Sonja Loges, Melanie Janning   +17 more
wiley   +1 more source

Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of ‘‐mabs’?

The Journal of Pathology, Volume 270, Issue 2, Page 139-162, October 2026.
Abstract Prostate cancer (PCa) is the second most common type of neoplasm, currently treated with a variety of therapeutic agents. Although advances in treatment over the past decade have improved overall survival, patients with advanced PCa eventually progress from hormone‐sensitive PCa to metastatic castration‐resistant PCa.
Giuseppe Schepisi, Irene Torresan, Emilio Francesco Giunta, Sara Bleve, Nicole Brighi, Elisa Tassinari, Sofia Zanuccoli, Maria Concetta Cursano, Cristian Lolli   +8 more
wiley   +1 more source

Combination Treatment of Docetaxel Liposomes and Sonodynamic Therapy With Verteporfin Liposomes in Patients With Cancer: A Report of Three Cases. [PDF]

Case Rep Oncol Med
Komura Y, Kimura S, Hirasawa Y, Takasaki R, Fukuro S, Thi NTM, Gengou M, Woo LS, Imataki O, Yanagawa T, Homma K.   +10 more
europepmc   +1 more source

Docetaxel in the treatment of squamous cell carcinoma of the head and neck

, 2008
Alexander Rapidis1, Nicholas Sarlis2, Jean-Louis Lefebvre3, Merrill Kies41Department of Maxillofacial Surgery, Greek Anticancer Institute, Saint Savvas Hospital, Athens, Greece; 2Department of Medical Affairs, Oncology – US Sanofi-Aventis ...
Alexander Rapidis, Nicholas Sarlis, Jean-Louis Lefebvre, Merrill Kies   +3 more
core  

Ablative radiotherapy in castration‐resistant prostate cancer

BJU International, Volume 138, Issue 4, Page 659-665, October 2026.
Objective To prove the oncological benefit of ablative radiotherapy in patients with up to five metastases from castration‐resistant prostate cancer (CRPC) a single‐centre randomised trial was initiated. Patients and Methods This monocentric, randomised, phase II clinical trial enrolled patients with up to five prostate‐specific membrane antigen ...
Tobias Hölscher, Fabian Lohaus, Lydia Koi, Jörg Kotzerke, Sebastian Hoberück, Christian Thomas, Angelika Borkowetz, Steffen Löck, Mechthild Krause, Esther G.C. Troost   +9 more
wiley   +1 more source

Transferrin-Conjugated, Camptothecin-Bearing Dendrimersomes Entrapping Docetaxel as a Dual-Drug Nanoplatform for Targeted Prostate Cancer Therapy. [PDF]

Pharmaceutics
Albatsh M, Al-Quraishi Z, Laskar P, Somani S, Irving C, Mackenzie GR, Woods S, Roberts CW, Mullin M, Dufès C.   +9 more
europepmc   +1 more source

Multifunctional gold nanorods and docetaxel-encapsulated liposomes for combined thermo- and chemotherapy

, 2017
Haiying Hua,1,* Nan Zhang,2,3,* Dan Liu,1 Lili Song,1 Tuanbing Liu,2,3 Shasha Li,2,3 Yongxing Zhao2,3 1Academy of Medical and Pharmaceutical Sciences, 2Department of Pharmaceutics, School of Pharmaceutical Sciences, Zhengzhou University, 3Key Laboratory
Song L, Hua H, Li S, Zhang N, Liu D, Liu T, Zhao Y   +6 more
core  

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

Molecular Oncology, Volume 20, Issue 9, Page 2175-2187, September 2026.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi, Stavros Makrodimitris, Sandra van Wilpe, Iris te Paske, Vanja de Weerd, Corine M. Beaufort, Hans M. Westgeest, Jens Voortman, Maureen J. B. Aarts, Maud Rijnders, Astrid A. M. van der Veldt, Ronald de Wit, Niven Mehra, Saskia M. Wilting, Debbie G. J. Robbrecht   +14 more
wiley   +1 more source